Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 infection~* In the judgement of the investigator, it is appropriate to initiate ARV therapy based on the patients medical condition and taking into account applicable guidelines for the treatment of HIV-1 infection~* Patient has access to an investigator-selected ARV regimen post-study in accordance with applicable guidelines for the treatment of HIV-1 infection~* HIV-1 plasma viral load at screening \>= 5000 HIV-1 RNA (copies/ml)~* Predicted phenotypic sensitivity to the currently approved NNRTIs and to the N(t)RTIs in their background regimen at screening~Exclusion Criteria:~* Any previous treatment with a therapeutic HIV vaccine or use of ARVs, including use of NVP for the prevention of vertical HIV transmission~* The presence of at least one of the mutations that are specific indicators of transmitted (or primary) drug resistance~* Known infection with HIV-2 or with HIV-1 group O~* Category C AIDS defining illness, except stable Kaposi's Sarcoma, wasting syndrome if not progressive~* Pneumocystis jiroveci/carinii Pneumonia (PCP) that is considered not cured~* Specific grade 3 or 4 laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- etravirine (Type: EXPERIMENTAL): etravirine (ETR TMC125) 400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
- efavirenz (Type: ACTIVE_COMPARATOR): efavirenz (EFV) 600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).